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I. INTRODUCTION
In 2003, seven organizations1 from around the world collaborated to
create the Drugs for Neglected Diseases initiative (DNDi)—an
organization to address the current imbalance in the development of drugs
1. Drugs for Neglected Diseases initiative (DNDi) was created by “the Oswaldo Cruz Foundation
from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the
Ministry of Health of Malaysia and France’s Pasteur Institute; one humanitarian organization, Médecins
sans Frontières (MSF); and one international research organization, the UNDP/World Bank/WHO’s
Special Programme for Research and Training in Tropical Diseases.” The Drugs for Neglected Diseases
Initiative
–
DNDi,
WORLD
HEALTH
ORG.,
http://www.who.int/trypanosomiasis_african/partners/dndi/en/ (last visited May 3, 2016).
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for diseases affecting poor populations.2 While approximately $240.00 of
public funding is spent per person on pharmaceutical research in developed
countries, only $20.00 is spent per person in developing countries, and only
$6.00 per head in sub-Saharan Africa.3 This public funding significantly
incentivizes manufacturers in developed countries to research and develop
new treatments, while the lack thereof impedes drug development in less
developed countries. 4
Once a new drug is on the market, the cost of developing the drug is
more likely to be recovered in developed nations, where patients have
higher incomes and can afford treatment. In contrast, potential customers in
poorer countries are unlikely to be able to pay a price for the drug that will
allow the manufacturer to recoup the cost of developing it. 5 This lack of
support for research and development has contributed to over seventeen
diseases in developing countries being neglected by research efforts.6 In
fact, drugs that treat diseases that are more prevalent in the developed
world, such as cancers and conditions of the central nervous system, are
thirteen times more likely to be developed than a drug for a neglected
disease, such as a parasitic disease. 7 For example, 1393 new chemical
compounds were authorized worldwide between 1975 and 1999, but only
sixteen of these were for tropical diseases.8
In May 2013, the World Health Organization’s 66th World Health
Assembly adopted resolution WHA66.12, in which Member States
resolved to enhance efforts to reduce the worldwide impact of neglected
tropical diseases (NTD), with a specific focus on completely eradicating
two NTDs by 2020.9 The criteria listed for a disease to qualify as a NTD
includes: (1) the disease is disproportionately prevalent among people

2. DRUGS FOR NEGLECTED DISEASES INITIATIVE, Vision & Mission, http://www.dndi.org/aboutdndi/vision-mission/ (last visited May 5, 2016).
3. Patrice Trouiller et al., Drug Development for Neglected Diseases: A Deficient Market and a
Public-Health Policy Failure, 359 THE LANCET 2188, 2191 (2002).
4. Id.
5. Philip Stevens, Diseases of Poverty and the 10/90 Gap, WORLD HEALTH ORG. (Nov. 2004),
http://who.int/intellectualproperty/submissions/InternationalPolicyNetwork.pdf.
6. There is some disagreement over the number of neglected diseases. See infra Part II. Section
A.
7. Patrice Trouiller et al., Drug development for neglected diseases: a deficient market and a
public-health
policy
failure,
PublicHealth
359
THE
LANCET
2188
(2002).
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.620.5966&rep=rep1&type=pdf.
8. Trouiller et al., supra note 3, at 2188.
9. WORLD HEALTH ORG. [WHO], Accelerating Work to Overcome the Global Impact of
Neglected Tropical Diseases: A Roadmap for Implementation, WHO/HTM/NTD/2012.1 (2012),
http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf.
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living in poverty, causing unique morbidity and mortality considerations
such as stigma, discrimination, and perpetuated poverty; (2) the disease
predominantly affects tropical areas; (3) the disease may be immediately
controlled or eradicated through application of the five public health
strategies adopted by the Department for Control of NTDs,10 or (4) the
disease has generally been ignored by research initiatives and resource
allocations. In order to qualify, a disease must either meet a combination of
criteria (1), (2), and (3) or criteria (1), (2), and (4).11
Overall, neglected diseases affect 1 billion people—about one-sixth of
the world’s population—but neglected diseases are not proportionally
addressed.12 These neglected diseases include: “Buruli ulcer disease,
Chagas disease, dengue and chikungunya, dracunculiasis, echinococcosis,
endemic treponematoses (yaws), foodborne trematodiases, human African
trypanosomiasis,
leishmaniasis,
leprosy,
lymphatic
filariasis,
onchocerciasis, rabies, schistosomiasis, soil-transmitted helminthiases,
taeniasis/cysticercosis and trachoma.”13 Treatment regimens for these
diseases fall under two categories: tool-ready, and “tool-deficient”,
depending on how much research has been done, and how much more is
needed to control the diseases.14
This paper addresses the imbalance in the development of treatments
for neglected diseases. It analyzes the causes behind the imbalances, and
the current legal and societal initiatives that are in place to address the
diseases. In particular, the paper suggests that the current patent system
fails to effectively incentivize the development of treatment for neglected
diseases. It further argues that the current international patent landscape
creates some Band-Aid solutions to pharmaceutical access in developing
countries in times of need, but does not adequately foster research and

10. These strategies include: “(i) preventive chemotherapy; (ii) innovative and intensified diseasemanagement; (iii) vector control and pesticide management; (iv) veterinary public health; and (v)
provision of safe drinking water, sanitation, and hygiene education.” e-Recruitment- Scientist, Vector
and Ecology Management (HQ.16/NTD/FT256), WORLD HEALTH ORG. (Oct. 22, 2016),
https://erecruit.who.int/public/hrd-cl-vac-view.asp?o_c=1000&jobinfo_uid_c=33428&vaclng=en.
11. Recommendation for the Adoption of Additional Diseases as Neglected Tropical Diseases,
WORLD
HEATH
ORG.
(2013),
http://www.who.int/neglected_diseases/diseases/Adoption_additional_NTDs.pdf?ua=1
[hereinafter
WHO Recommendation].
12. CTRS. FOR DISEASE CONTROL AND PREVENTION, Neglected Tropical Diseases,
http://www.cdc.gov/globalhealth/ntd/ (last updated June 7, 2016).
13. See WHO Recommendation, supra note 10; but see Trouiller et al., supra note 3, at 2188.
14. For neglected tropical diseases, pocket change goes a long way, CTR. FOR HIGH IMPACT
PHILANTHROPY (Sept. 14, 2010), http://endtheneglect.org/2010/09/for-neglected-tropical-diseases-0-40goes-a-long-way/.
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development in these areas. As a result of these shortcomings, developing
countries are unable to enhance their own research and manufacturing
capacities to meet their unique drug needs, and pharmaceutical companies
in developed countries lack incentives to develop treatment for diseases
impacting the world’s poorest populations. Finally, this paper offers some
recommendations about how the current status of treatment can be
improved.
II. BACKGROUND ON NEGLECTED TROPICAL DISEASES
A. Neglected Diseases: What are they?
There is some debate regarding the number of neglected diseases, and
estimates range from twelve15 to over thirty.16 The World Health
Organization has identified seventeen tropical neglected diseases as most
important and the ones that it plans to focus on. The diseases are divided
into four main groups of pathogens: (1) Protozoa (i.e. Chagas disease,
human African trypanosomiasis, leishmaniases); (2) Bacteria (Buruli ulcer,
leprosy, trachoma, yaws); (3) Helminths or Metazoan worms (i.e.
cysticercosis/taeniasis,
dracunculiasis,
echinococcosis,
foodborne
trematodiases, lymphatic filariasis, onchocerciasis, schistosomiasis, soiltransmitted helminthiasis); and (4) Viruses (dengue and chikungunya,
rabies).17 As all of these are parasitic infections, NTDs occur most
commonly in areas of poverty and poor sanitation, including areas with
polluted water sources, livestock, and infection vectors. 18 Many of these
illnesses disproportionately impact women and children because these
groups tend to be most in contact with disease agents. 19
Some of the diseases can be treated or prevented with existing
technologies but have not yet been eliminated due to poor health policies
and lack of organized action against the diseases. These tool-ready
15. Alan Fenwick, The Global Burden of Neglected Tropical Diseases, 3 PUBLIC HEALTH 233,
234 (Mar. 2012).
16. Kamal K. Midha, Presidential Address at the FIP Congress Opening Ceremony, 25 INT’L
PHARM. J. 4 (Dec. 2009), available at https://www.fip.org/files/fip/IPJ/IPJ_2009V25web.pdf.
17. Neglected
Tropical
Diseases,
WORLD HEALTH ORG.
(Nov. 24, 2015),
http://www.who.int/neglected_diseases/diseases/en/. See also Lecture Notes: TROPICAL MEDICINE
th
(Geoff Gill & Nick Beeching eds., 6 ed. 2011) (discussing the categorization of tropical diseases).
18. Neglected
Tropical Diseases,
WORLD HEALTH ORG.
(Nov. 24, 2015),
http://www.who.int/neglected_diseases/diseases/en/.
19. THE HENRY J. KAISER FAMILY FOUND., The U.S. Government and Global Neglected Tropical
Disease Efforts (July 19, 2016), http://kff.org/global-health-policy/fact-sheet/the-u-s-government-andglobal-neglected-tropical-diseases/ [hereinafter KAISER].
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diseases, such as foodborne trematode infections, lymphatic filariasis,
onchocerciasis, schistosomiasis, soil-transmitted helminthiases and
trachoma could be prevented by coordinating large-scale, single-dose
administration of therapies, 20 such as vaccines, immune-booster pills, and
other long-lasting treatment. 21 For example, a four-drug concoction works
to prevent up to seven diseases, but needs to be administered across a large
population to control against re-contamination.22 Some regions already
have control programs set up to provide mass drug administrations (or
MDAs) to populations prone to the disease.23 Other NTDs such as Buruli
ulcer, endemic treponematoses (yaws), leprosy (Hansen disease), Chagas
disease, human African trypanosomiasis (sleeping sickness), leishmaniasis,
cysticercosis and echinococcosis will require new technologies, tools and
strategies to eliminate. 24 Some of the diseases cannot be treated with
existing MDA programs, or will require individual diagnostic and
treatment mechanisms that involve more resources. Overall, the total cost
of eliminating or eradicating neglected diseases from the world is estimated
to be only $1.5 to 2 billion, if it is employed in conjunction with human
resources and policy measures. 25 This method of treatment would cost less
than fifty cents per person per year but would require considerable
governmental and private sector cooperation to organize and administer. 26
Section B. of this paper further discusses the governmental and social
initiatives that could be implemented to accelerate the elimination of these
diseases.

20. LORENZO SAVIOLOI ET AL., WORLD HEALTH ORG., A ROADMAP FOR IMPLEMENTATION 1
(David
W.T.
Crompton
ed.
2012),
http://apps.who.int/iris/bitstream/10665/70809/1/WHO_HTM_NTD_2012.1_eng.pdf [hereinafter WHO
ROADMAP].
21. Jeffrey M. Bethony et al., Vaccines to Combat the Neglected Tropical Diseases, 239
IMMUNOL REV. 237, 242–46 (2011).
22. SABIN VACCINE INST., The Solution, GLOBAL NETWORK| NEGLECTED TROPICAL DISEASES,
http://www.globalnetwork.org/solution (last visited May 10, 2016).
23. SABIN VACCINE INST., The Most Common NTDs, GLOBAL NETWORK| NEGLECTED TROPICAL
DISEASES, http://www.globalnetwork.org/neglected-tropical-diseases/fact-sheets (last visited Sept. 23,
2016).
24. WHO ROADMAP, supra note 19, at 1; CTRS. FOR DISEASE CONTROL AND PREVENTION,
Neglected
Tropical
Diseases,
Other
NTDs,
http://www.cdc.gov/globalhealth/ntd/diseases/otherntds.html (last visited May 10, 2016).
25. Fenwick, supra note 14, at 235.
26. CTRS. FOR DISEASE CONTROL AND PREVENTION, Neglected Tropical Diseases—Fast Facts,
http://www.cdc.gov/globalhealth/ntd/fastfacts.html (last visited May 4, 2016).
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B. Current Legal and Social Initiatives in Place to Address Neglected
Diseases
Section 740 of the Agriculture, Rural Development, Food and Drug
Administration, and Related Agencies Appropriation Act of 2010
(Appropriation Act) states that the Commissioner of Food and Drugs of the
U.S. Food and Drug Administration (FDA) shall establish a “review group
which shall recommend . . . appropriate preclinical, trial design, and
regulatory paradigms and optimal solutions for the prevention, diagnosis,
and treatment of neglected diseases of the developing world.”27 In July
2014, the FDA released its Guidance for Industry regarding Section 740 of
the Appropriation Act. The FDA Guidance states that NTD applications
will be reviewed as Investigative New Drug (IND) applications, regardless
of where clinical trials take place. The same regulatory and review standard
will be applied to NTD therapies as is applied to diseases endemic to the
United States. 28 Specifically, the Guidance gives the FDA “considerable
latitude to exercise its scientific judgment to determine the kind and quality
of data and information an applicant is required to provide . . . to meet the
statutory standards” for NTD approval.29 The FDA commits to weigh the
severity of the NTD against the quality of alternative therapies (or lack
thereof) in determining whether the benefits of therapy outweigh risks.30
Finally, the FDA acknowledges that certain circumstances may justify
requiring only one, well-controlled clinical trial for approval of an NTD
drug.31
Section 524(b)(1) of the Food, Drug and Cosmetic (FD&C) Act
formally acknowledges seventeen “tropical diseases” that have been
neglected by traditional medical efforts.32 In addition, Section 524 of the
FD&C Act introduces priority review vouchers for pharmaceutical
manufacturers or sponsors that develop treatment for NTDs. A priority
review voucher “entitles the holder of such voucher to priority review of a

27. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriation Act, Pub. L. No. 111-80, § 740(b) (2010).
28. U.S. DEP’T OF HEALTH AND HUMAN SERV., FOOD AND DRUG ADMIN., GUIDANCE FOR
INDUSTRY NEGLECTED TROPICAL DISEASES OF THE DEVELOPING WORLD: DEVELOPING DRUGS FOR
TREATMENT
OR
PREVENTION,
2
(2014),
available
at
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm269221
.pdf [hereinafter FDA GUIDANCE].
29. Id. at 5; see also 21 C.F.R. § 314.105(c) (2008).
30. 21 C.F.R. § 312.84(a) (2008).
31. FDA GUIDANCE, supra note 27.
32. 21 U.S.C. § 360n(a)(3) (2016).
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single human drug application submitted under section 355(b)(1) of this
title or section 262 of title 42 after the . . . approval of the tropical disease
product application.” Hence, the sponsor of the tropical disease application
can use the voucher to expedite review of one of its more profitable
drugs.33 These public policies have been geared toward diseases that do not
have current treatment options, or need new vaccine generations. However,
existing international patent laws impact drugs that are already available
but expensive or unavailable in developing countries due to patent rights.34
Between 1986 and 1994, World Trade Organization (WTO) drafted
the Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPS Agreement) to establish international standards for intellectual
property rights and grant equal rights in all member countries. 35 The TRIPS
Agreement provides specific provisions relating to patents. First, it requires
that patents be available in every field, including, pharmaceuticals and
medical devices, which were previously not patentable in many countries.36
Second, the national treatment provision requires countries to grant
inventors from other countries the same rights as it grants to its own
citizens. The most-favored-nation provision states that if a member nation
grants one of its trading partners a special IP protection, it must grant that
protection to all other member nations.37
Some exceptions may be made for countries that need to provide their
population with emergency “diagnostic, therapeutic and surgical
methods.”38 Article 27 of TRIPS permits a suspension of patent rights to
protect “ordre public or morality.” However, it has not been properly
defined what constitutes “ordre public or morality” and the term continues
to be debated.39 Article 30 permits “limited exceptions” to patent rights,
granted they do not unreasonably interfere with the patent holder’s rights.40

33. 21 U.S.C. § 360n(a)(2) (2016).
34. Kyle Wamstad, Priority Review Vouchers: A Piece of the Incentive Puzzle, 14 VA. J.L. &
TECH. 126, 135 (2009).
35. Intellectual
property:
protection
and enforcement,
WORLD TRADE ORG.,
https://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm (last visited May 5, 2016).
36. Agreement on Trade Related Aspects of Intellectual Property Rights art. 27, Apr. 15, 1994, 33
I.L.M. 81 [hereinafter TRIPS Agreement].
37. Principles
of
the
Trading
System,
WORLD
TRADE
ORG.,
https://www.wto.org/english/thewto_e/whatis_e/tif_e/fact2_e.htm#national (last visited Oct. 22, 2016).
38. UNIVERSITY OF KERALA DEPARTMENT OF LAW, Exclusion of Diagnostic, Therapeutic, and
Surgical Methods from Patentability. 18 J. INTELL. PROP. RTS. 242, 242-50 (2013).
39. TRIPS Agreement, supra note 35, art. 27, at 93-94.
40. TRIPS Agreement, supra note 35, art. 30, at 95.
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Article 31 allows exceptions for “national emergency or other
circumstances of extreme urgency” where a government may circumvent
patent rights without authorization of the right holder “for other use . . . of
the subject matter of [the] patent,”41 implying “use other than that allowed
under Article 30.”42 This article allows governments to occasionally grant
compulsory licenses without negotiating with the patent owner, as long as
the license is for a national emergency and noncommercial public use. 43 A
compulsory license authorizes the government or a third party country to
manufacture a generic drug, with the condition that (1) it will
predominantly supply the domestic market;44 and (2) the patent holder will
be compensated based on the value of the license. 45
However, there is considerable debate regarding what constitutes a
national emergency, and when this exception is permissible. The United
States has insisted that developing countries are responsible for TRIPS
provisions following 2005, which was the end of the adjustment grace
period afforded to developing countries. However, developing countries
argue that their economies are not prepared for a full-blown, U.S. style
patent system, as they must prioritize other basic human needs such as
affordable access to health care. 46
In response to this debate, member nations reconvened to resolve
some of these controversies and questions, and created the 2001 Doha
Declaration on TRIPS and Public Health (Doha Declaration). 47 The Doha
Declaration affirmed the importance of the “right to protect public health
and, in particular, to promote access to medicines for all”, and affirmed
“the right of WTO Members to use, to the full, the provisions in the TRIPS
Agreement, which provide flexibility for this purpose.”48 In addition, the
Doha Declaration clarified that each country has the right to define a
41. TRIPS Agreement, supra note 35, art. 31, at 95.
42. TRIPS Agreement, supra note 35, n.7, at 111.
43. TRIPS Agreement, supra note 35, art. 31(b), at 95.
44. TRIPS Agreement, supra note 35, art. 31(f), at 95.
45. TRIPS Agreement, supra note 35, art. 31(h), at 95.
46. See Kimberly A. Czub, Argentina’s Emerging Standard of Intellectual Property Protection: A
Case Study of the Underlying Conflicts Between Developing Counties, TRIPS Standards, and the
United States, 33 CASE W. RES. J. INT’L L. 191, 199–202 (2001); Robert C. Bird, Developing Nations
and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment
Side-Effects, 37 J.L. MED. & ETHICS 209, 210 (2009).
47. James Thuo Gathii, The Legal Status of the Doha Declaration on TRIPS and Public Health
and the Vienna Convention on the Law of Treaties, 15 HARV. J.L. & TECH. 291, 292 (2009).
48. World Trade Organization, Ministerial Declaration of 14 November 2001, ¶ 4, WTO Doc.
WT/MIN(01)/DEC/1,
41
ILM
(2001),
available
at
https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_e.pdf [hereinafter Doha Declaration].
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national emergency for itself, and that epidemics of any disease can always
qualify as national emergencies. The Doha Declaration further clarified that
compulsory licenses are permissible at any time during these national
emergencies, even after a developing nation has fully adopted the TRIPS
Agreement.49 Finally, recognizing that compulsory licenses may not be
feasible for least developed nations that lack resources to manufacture the
drugs, the Doha Declaration provided the option of parallel importation,
which allows nations to import certain amounts of pre-made
pharmaceuticals in return for reasonable compensation. 50 Usually, the
pharmaceutical companies will be able to sell the drugs cheaper in poorer
countries, and recover costs with higher prices in developed countries. 51
Alternatively, third-party countries could apply for compulsory licenses,
produce the biologic drugs, and provide them to least developed countries
through parallel importation. 52
III. ARGUMENT/ANALYSIS
A. Why Should We Care?: Impact of the Neglected Diseases on
Communities—Overseas and In the United States
The United States has fought long and hard to preserve the current
status of international IP rights, which theoretically aims to gradually
transfer all countries’ IP programs to look like the U.S.’s.53 While this
might be a strong system in the long run, the U.S. and the rest of the world
would benefit from a flexible and more country-specific IP system in the
beginning, which later transitions into a uniform system. The concept of
providing private companies incentives for developing novel, useful
technologies has benefited several countries in promoting innovation.54
This system could be used in a similar, but tailored way, to incentivize

49. Parallel
Imports,
WORLD
HEALTH
ORG.
(May
12,
2016),
http://www.who.int/trade/glossary/story070/en/.
50. Id.
51. Id.
52. C. James Attridge & Alexander S. Preker, IMPROVING ACCESS TO MEDICINES IN DEVELOPING
COUNTRIES APPLICATION OF NEW INSTITUTIONAL ECONOMICS TO THE ANALYSIS OF MANUFACTURING
AND
DISTRIBUTION
ISSUES,
28
(Mar.
2005),
available
at
http://apps.who.int/medicinedocs/documents/s16743e/s16743e.pdf.
53. Robert C. Bird, Developing Nations and the Compulsory License: Maximizing Access to
Essential Medicines While Minimizing Investment Side-Effects, 37 J.L. MED. & ETHICS 209, 210
(2009).
54. Gene Quinn, The Story of How Patents Promote Innovation, IPWATCHDOG (May 12, 2014),
http://www.ipwatchdog.com/2014/05/12/the-story-of-how-patents-promote-innovation/id=49520/.
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innovation in developing countries. Implementing a flexible and tailored
system according to each country’s developmental status and needs will
benefit the entire world because developing countries will eventually be
able to contribute more to technological advancements and emerge with
stronger economies. 55
Furthermore, all countries in the world have an inherent self-interest in
helping eliminate or control neglected diseases, which currently cause
many young people to experience life-long disability, discrimination,
stigma, and sometimes death. 56 These living conditions lead communities
into a state of distress, and prevent them from exiting poverty, leaving the
community economically dependent on humanitarian efforts and
government resources to pay for health care, food, and sanitation. 57 In
addition, the community is less productive and unable to contribute to the
development of its country.58 Neglected diseases are also confounded with
other diseases such as malaria, HIV, and tuberculosis, which causes
heightened morbidity and mortality among people suffering from neglected
diseases.59 Therefore, in order to see an expedited elimination of these
three big diseases, it is important to address collateral disease factors,
including neglected diseases.60
The improvement in the health system of developing countries will
lead to economic progress, which will in turn lead to a more robust IP
system over time. The shift to a more U.S.-like patent system will benefit
U.S. pharmaceutical companies, which will then be able to pursue more
meaningful IP protection in foreign countries in the future. The local
populations in developing countries will also be more financially capable
of affording U.S.-developed pharmaceuticals. 61
Some scholars have argued that countries suffering from NTDs are of
interest to the United States for foreign policy reasons; therefore, advancing
55. Ileana Dominguez-Urban, Harmonization in the Regulation of Pharmaceutical Research and
Human Rights: The Need to Think Globally, 30 CORNELL INT’L L.J. 245, 253 (1997).
56. See generally, Id.
57. PETER J. HOTEZ, The Neglected Tropical Diseases and the Neglected Infections of Poverty:
Overview of Their Common Features, Global Disease Burden and Distribution, New Control Tools,
and Prospects for Elimination, in THE CAUSES AND IMPACTS OF NEGLECTED TROPICAL AND ZOONOTIC
DISEASES: OPPORTUNITIES FOR INTEGRATED INTERVENTION STRATEGIES 221, 231-32 (2011), available
at http://www.ncbi.nlm.nih.gov/books/NBK62521/.
58. WHO Recommendation, supra note 10, at 1.
59. Mike Shanahan, ‘Beat neglected diseases’ to fight HIV, TB and malaria, SCIDEV.NET (Jan.
31, 2006), http://www.scidev.net/global/disease/news/beat-neglected-diseases-to-fight-hiv-tb-andmal.html.
60. Hoetz, supra note 57.
61. See generally Dominguez-Urban, supra note 53, at 253.
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the elimination of NTDs would serve as a “low-cost yet high-profile”
humanitarian effort for the U.S., with a high chance of success. Finally,
Hotez and Thompson believe that poverty and isolation caused by NTDs
promote conflicts in the world’s Islamic nations, which may possess
nuclear weapons and could pose threats to the United States and their own
regions.62 This threat of increased conflict adds urgency to the world’s
purpose to ultimately eliminate NTDs. Collaborative research and
development projects between the United States and Islamic countries to
eliminate NTDs from unstable or conflict-ridden states and to develop a
new generation of NTD vaccines, could build relationships between the
regions, similar to the cooperation between the United States and former
Soviet Union on polio and smallpox treatment development in the 20th
century.63
B. Reasons for the Lag in Treatment Development for Neglected Tropical
Diseases
Neglected diseases are a product of several factors, including a lack of
governmental health initiatives, poor health policies, and misapplied patent
laws. NTDs disproportionately impact low income countries, in Africa,
Asia and South America, and tropical areas of the Caribbean. 64 Because
each neglected disease does not have a high death toll or rapid-onset death,
they often do not receive wide-spread publicity or media attention.
However, they often occur in combination with each other and lead to longterm, debilitating conditions that prevent individuals from engaging in
daily activities such as going to work or school.65 This traps the individuals
in these communities in a cycle of poverty, whereby they continue to lack
access to sanitary food, water and housing, which exposes them to more
diseases.66 This paper briefly touches on the broad governmental and social
factors that impact the status of neglected diseases; and then focuses
particularly on IP factors that are preventing development of new treatment
and prevention technologies for neglected diseases.
62. Hoetz, supra note 57.
63. Peter J. Hotez & Tommy G. Thompson, Waging Peace Through Neglected Tropical Disease
Control: A US Foreign Policy for the Bottom Billion, PLOS NEGLECTED TROPICAL DISEASES, Jan.
2009, at 1, 3; Hotez, supra note 56, at 233-34.
64. NAT’L INST. OF HEALTH, Neglected Diseases, Genetic and Rare Diseases,
https://rarediseases.info.nih.gov/files/neglected_diseases_faqs.pdf (last visited May 11, 2016).
65. KAISER, supra note 18.
66. Thomas Kariuki et al., Research and Capacity Building for Control of Neglected Tropical
Diseases: The Need for a Different Approach, PLOS NEGLECTED TROPICAL DISEASES, May 2011, at 1.
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i. Social, Scientific and Governmental Actions That Hinder the
Development of Neglected Disease Treatment
Neglected diseases affect the world’s poorest and most vulnerable
populations, and have been ignored due to a lack of political will, scientific
advancement, and funds. For instance, NTDs represent a class of diseases
that have especially complex genomes (particularly the eukaryotic67
pathogens), making it a challenge to develop in vitro systems to maintain
the NTD pathogens in the laboratory. It is also difficult to discover suitable
animal models of the diseases, and adequate correlates of protection, such
as antibodies.68 Without these experimental materials and methods, it is
hard to develop antigens, adjuvants, and other platform technologies,
making it challenging to manufacture an administrable treatment. 69 In
addition, many of these platform technologies are patented, therefore only
available to richer populations. 70 Some of the patent solutions discussed in
the second part of this section will also address these scientific
shortcomings.
Due to the scientific complexity of NTDs, the cost of developing new
technologies to address outbreaks is high. Because the diseases mostly
impact people living in poverty, the target patients are not able to afford the
price of the drugs. Even for tool-ready diseases, for which some form of
treatment is available, governments do not have enough incentives to
update treatment, coordinate mass-administration programs, or implement a
system of diagnosis and treatment. 71
In contrast, diseases such as HIV/AIDS, malaria, and tuberculosis
have received far more publicity and funding, through their prominent
inclusion in the Millennium Development Goals, where neglected diseases
were only referred to as “other diseases.”72 International efforts such as the
U.S. President’s Emergency Plan for AIDS Relief , the U.S. President’s
Malaria Initiative, and the Global Fund to Fight AIDS, Tuberculosis, and

67. Organisms whose cells have membrane-bound organelles, such as a nucleus. Eukaryotic Cell
v. Prokaryotic Cell, DIFFEN, http://www.diffen.com/difference/Eukaryotic_Cell_vs_Prokaryotic_Cell
(last visited May 3, 2016).
68. Bethony et al., supra note 20, at 242.
69. Global Funding of Innovation for Neglected Diseases: G-FINDER, POLICY CURES
http://www.policycures.org/downloads/G-FINDER_Year_3_summary.pdf (last visited May 11, 2016).
70. Jason Macleod, TB DIAGNOSTIC DEVELOPMENT IN THE DEVELOPING WORLD – IP SOLUTIONS
THROUGH PUBLIC PRIVATE PARTNERSHIPS, https://www.jasondmacleod.com/law-articles/tb-diagnosticdevelopment-developing-world-ip-solutions-public-private-partnerships/ (last visited May 1, 2016).
71. WHO RECOMMENDATION, supra note 10.
72. Bethony et al., supra note 20, at 237-38.
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Malaria, provided millions of people antiretrovirals, antimalarial drugs and
insecticide-treated nets.73 Public private partnerships formed to develop and
test new vaccines, through support from the Bill & Melinda Gates
Foundation, the US National Institutes of Health, and the Wellcome
Trust.74 As a result of the international effort to address these illnesses, the
malaria mortality rate declined by 58% between 2000 and 2015. And, by
2014, 13.6 million people globally were receiving antiretroviral therapy
(ART) for HIV infection, while new infection rates dropped by 40%. Plus,
nearly 37 million lives have been saved between 2000 and 2013 as a result
of tuberculosis initiatives.75

Other recent diseases, such as Zika and Ebola, have spread to
the developed nations across the West, sparking international
pressure and global efforts to develop a treatment.” Most NTDs do
not spread quickly to developed nations, eliminating the immediate
need for rich countries to invest in treatment development.76 For
example, although parasitic infections account for one-third of the
world’s total disease burden and are more prevalent in the
developing world, they only account for 5% of diseases in the
developed world.77 As international travel and trade increase, the
world will be more at risk of diseases spreading rapidly on an
international scale, pushing all countries to engage in a collaborative
effort to reduce the impacts.78
Hence, a successful solution to the neglected disease problem will
have to be multi-faceted, and will likely include new regulation, social and
humanitarian initiatives, and intellectual property (IP) reform. These
strategies for reform are discussed below.

73. Peter J. Hotez, FORGOTTEN PEOPLE, FORGOTTEN DISEASES: THE NEGLECTED TROPICAL
DISEASES AND THEIR IMPACT ON GLOBAL HEALTH AND DEVELOPMENT 3 (Am. Soc’y for Microbiology
Press ed., 2nd ed. 2008).
74. Bethony et al., supra note 20, at 238.
75. U.N. Secretary-General, MILLENNIUM DEVELOPMENT GOALS REPORT, Goal 6: Combat
HIV/AIDS,
Malaria,
and
Other
Diseases
(2015)
http://www.un.org/millenniumgoals/2015_MDG_Report/pdf/MDG%202015%20rev%20(July%201).pd
f.
76. WHO RECOMMENDATION, supra note 10.
77. Trouiller et al., supra note 3, at 2188.
78. Dr. Mary Moran et al., NEGLECTED DISEASE RESEARCH AND DEVELOPMENT: THE
EBOLA
EFFECT,
POLICY
CURES,
http://policycures.org/downloads/Y8%20GFINDER%20full%20report%20web.pdf (last visited Oct. 25,
2016).
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ii. Current Patent Law and its Impact on Disease Treatment Development
The TRIPs Agreement benefits countries and companies that
introduce innovative products into the developing markets and wish to seek
IP protection. For example, U.S. pharmaceutical companies can
theoretically obtain patents for new pharmaceuticals in Asia and Africa,
under similar patent terms as the U.S. 79 However, many of these countries
do not have the resources or infrastructure to invest in setting up a
comprehensive patent system. For example, developing countries
sometimes do not have IP offices and examiners to review patents, or
courts and judges to enforce them. They may also have different cultural
preferences, and not be interested in patent rights for medical instruments
for moral reasons.80 Hence, many scholars have argued that the TRIPs
Agreement favors a U.S.-style patent system and benefits developed
countries, but is not best suited to meet the needs of developing countries.
In addition, some scholars have argued that the current international IP
scheme has hindered access to essential medicines in developing countries,
because cheap generic versions of pharmaceuticals are slower to enter the
market, and because developing countries are unable to conduct research to
manufacture their own versions of medicines, due to over broad patenting
by U.S. pharmaceutical companies and potential infringement issues. 81
However, the biggest issue in IP is the fact that the implementation
has inhibited developing countries from taking full advantage of the
principles of an IP system. While some previous scholarship has suggested
that developing countries should disregard Western patenting ideals, it is
advisable to implement a less stringent version of patent rights to jumpstart
kick-start development of new technologies in emerging economies, and
eventually in less developed countries. This method will be more effective
than incentives such as the Doha Declaration, which allows countries to
grant compulsory licenses and parallel importation. While current
international initiatives such as the Doha Declaration provide some
emergency access to already developed treatment, they are a Band-Aid

79. Protecting Intellectual Property Rights (IPR) Overseas, U.S. PAT. AND TRADEMARK OFF.,
http://www.uspto.gov/patents-getting-started/international-protection/protecting-intellectual-propertyrights-ipr (last visited May 13, 2016).
80. Ganiyou Gassikia, Implementing and Enforcing Intellectual Property Right in West Africa
JOHN MARSHALL REV. INT. PROP., 782, 785 (2014). See also E. Richard Gold et al., Are Patents
Impeding Medical Care and Innovation? PLOS MED., Jan. 2009, at 1, 3.
81. Kristina Lybecker, Patent Law 2.0: Not the Answer the Developing World Needs,
IPWATCHDOG (Aug. 18, 2013), http://www.ipwatchdog.com/2013/08/18/patent-law-2-0-not-theanswer-the-developing-world-needs/id=44699/.
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solution, and do not encourage local development of treatment. Therefore,
this proposal also involves incentivizing U.S. pharmaceutical companies to
invest more in solutions for neglected diseases.82
IV. RECOMMENDATIONS
One way in which U.S. patent law could indirectly benefit developing
countries is through joint or collaborated research, and shared patent rights.
Drugs for diseases effecting the developed world could be the basis for
drugs that treat NTDs, and vice versa, as some diseases may be similar. 83
For example, Zika virus is in the same family at dengue and West Nile, and
the current search for a vaccine for Zika is drawing on previous findings
from the development of the dengue vaccine. 84 Once a Zika vaccine is
developed, the manufacturers will be best positioned to update the vaccine
for use in dengue, and other water-associated mosquito diseases.85
Additionally, diagnostic measures that are used for comparable diseases in
the United States and other developed countries could be used for neglected
diseases. However, many of these diagnostic procedures are patented,
which inhibits affordable diagnostics in developing countries.86
Second, another potential IP solution could involve treating different
developing countries differently. The preamble to the WTO Agreement,
which is the umbrella agreement for all WTO initiatives, including the
TRIPs Agreement, “Recogniz[es] that . . . relations in the field of trade and
economic endeavor should be conducted with a view to raising standards of
living, ensuring full employment and a large and steadily growing volume
of real income and effective demand, and expanding the production of and
trade in goods and services, while allowing for the optimal use of the
world’s resources in accordance with the objective of sustainable

82. See generally Angela J. Anderson, Global Pharmaceutical Patent Law in Developing
Countries- Amending TRIPS to Promote Access for All, BEPRESS LEGAL REPOSITORY (Mar. 2006),
http://law.bepress.com/expresso/eps/1109/.
83. See generally Hanna Waters, Patent-sharing Scheme for Neglected Diseases May Have Catch,
17 NATURE MEDICINE 1529 (2011).
84. Maggie Fox, New Dengue Vaccine May Form Basis for Zika Vaccine, NBC NEWS (Mar. 17,
2016, 12:08 PM), http://www.nbcnews.com/storyline/zika-virus-outbreak/new-dengue-vaccine-mayform-basis-zika-vaccine-n540851.
85. Veronica Sikka, et al., The Emergence of Zika Virus as a Global Health Security Threat: A
Review and a Consensus Statement of the INDUSEM Joint Working Group (JWG), 8 J. OF GLOBAL
INFECTIOUS DISEASES 3 (2016).
86. See, e.g., Catherine Jewell, Catalyzing research into neglected tropical diseases, WIPO MAG.
(Feb. 2013), http://www.wipo.int/wipo_magazine/en/2013/01/article_0004.html (discussing initiatives
to license diagnostic tools).
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development”.87 This differential treatment of countries based on their
economic and development status would be justified by the WTO
Agreement’s Preamble, which recognizes the “need for positive efforts
designed to ensure that developing countries, and especially the least
developed among them, secure a share in the growth in international trade
commensurate with the needs of their economic development,” indicating
that each developing country should be treated differently. 88 The reason the
U.S. patent system offers such a strong push for innovation is because the
system was carefully tailored to meet the needs of this country. Hence,
implementing a patent system that is unique to each developing country
will enable both U.S., and developing countries, to acquire increased access
to treatments but in a different manner. Instead of relying solely on imports
and compulsory licenses, developing countries will be able to use their
comparative advantages to set up manufacturing and innovation.
Developing countries possess cheap raw materials, fewer regulations for
clinical trials, and easier access to trial subjects, which will enable them to
eventually set up comprehensive and locally beneficial research centers. 89
While developed countries could continue to operate under the current
international patent framework, more flexible systems could be
implemented in developing countries. For instance, one reason why many
developing countries do not implement robust patent systems is because
they are expensive to run. Conducting patent searches, tracking the filing
process, and conducting examinations all require considerable resources. In
addition, not all countries aspire to grant patents for all fields or products.
Some countries exclude patents on food, agricultural products, and
chemical compounds.90 In achieving a more user-friendly patent system,
countries could lower the requirements for showing non-obviousness, could
limit the kinds of products that patents are available for, and could reduce
the number of years a patent term lasts. This would reduce the time to
review and grant a patent, and would release the invention into the public
domain in a shorter time frame. Implementing a system whereby local

87. Appellate Body Report, European Communities – Conditions for the Granting of Tariff
Preferences to Developing Countries, WTO Doc. WT/DS246/AB/R (Apr. 7, 2004).
88. Rohan K. George, Conference Paper, Does One Size Fit All? A Comparative Study to
Determine an Alternative to International Patent Harmonization, Cornell L. Libr. (2009).
89. Roy Zwahlen, Neglected Diseases: What if IP was the Cure?, BIOTECH NOW (Oct. 29, 2013),
http://www.biotech-now.org/public-policy/patently-biotech/2013/10/neglected-diseases-what-if-ip-wasthe-cure.
90. George, supra note 83, at 9.
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researchers and manufacturers are enabled to conduct clinical trials will be
a better long-term solution. 91
One way manufacturers are currently incentivized to develop drugs for
neglected diseases is through Priority Review Vouchers (PRV). A drug
manufacturer could get a PRV when it develops a treatment for a neglected
disease or a disease primarily affecting the developing world. The
manufacturer could apply the PRV to get priority review for one of its more
profitable drugs, or a blockbuster drug. This could potentially increase a
manufacturer’s profits by $300 million if it gains an extra six months on the
market. This solution increases incentives for branded and reference
product companies without extending patent terms or limiting generic
entrance.92 However, it may be used with regards to patents too. For
example, if a manufacturer develops a treatment for a neglected disease,
upon approval of that diseases, the manufacturer could be entitled to a
“priority examination voucher,” which could be used to hasten a patent
application examination for a blockbuster drug or a more profitable
invention.
In addition, if a government wants to further incentivize
implementation of the diseases treatment, it could condition the receipt of a
priority examination voucher on the company ensuring that the neglected
diseases treatment is property delivered and administered in an area of
need. Furthermore, the government could also provide vouchers for slightly
longer patent terms for another invention, if the manufacturing company
offers to sponsor other activities such as sanitization or deworming in
developing countries.
V. CONCLUSION
As the world becomes smaller and more interconnected, neglected
diseases are a growing international concern that must be addressed
through joint efforts between the developed and developing worlds. In
particular, discrete patent systems for developing countries, joint patents
and technology sharing agreements, and enhanced incentives for
pharmaceutical companies will contribute to controlling and eliminating
these diseases. Of course, these patent-related driving forces must he

91. Kameron W. Kramer, The High Value (and Cost) of Patents, ALBUQUERQUE BUS. L. (Oct. 12,
2011), http://www.albuquerquebusinesslaw.com/intellectual-property/the-high-value-and-cost-patents/.
92. Lesley Hamming, The Promise of Priority Review Vouchers as a Legislative Tool to
Encouraging Drugs for Neglected Diseases, 11 DUKE L. & TECH. REV. 390, 394 (2013).
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accompanied by governmental and societal initiatives in order to arrive at a
timely and comprehensive solution.

